Find News

Filter articles

Applied Filters

Showing 761 to 770 of 919 results

Teva records another victory in US Supreme Court Copaxone ruling

US20-01-2015Legal developments

The US Supreme Court has vacated an appeals court judgment that invalidated a patent covering Teva’s blockbuster drug Copaxone (glatiramer acetate).

Shionogi sues Aurobindo to halt Doribax generic

US19-01-2015Legal developments

Japanese pharmaceutical company Shionogi has sued Aurobindo Pharma in an attempt to stop the Indian generic drug maker from marketing a version of its antibiotic drug Doribax (doripenem) in the US.

Teva and Mylan get green light to launch Novartis generics


Pharmaceutical companies Teva and Mylan have each been granted permission to market a generic version of Novartis’s blood pressure treatment Diovan (valsartan) in the US.

Drug makers on brink of $65bn patent cliff, says report


Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.

Acne drug at centre of ‘first’ IPR ruling of its kind


Pharmaceutical company Supernus and its subsidiary Galderma have had their Oracea (doxycycline) acne treatment drug protected from a generic challenge, in a decision dubbed the “first of its kind”.

Merck insists on buyout despite generic blow


Pharmaceutical company Merck has said it will press on with an $8.4 billion buyout of Cubist Pharmaceuticals despite a court ruling that could pave the way for a generic version of a lucrative Cubist drug.

AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

India, US08-12-2014Legal developments

A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.

Ranbaxy sues FDA over drugs revoke

India, US19-11-2014

Indian drug maker Ranbaxy Laboratories has sued the US Food and Drug Administration and claimed it wrongfully revoked a previous approval for two new drugs.

Canadian Supreme Court case breaks down


A case that was expected to act as a benchmark for future patent cases in Canada has been settled a day before the country’s Supreme Court was due to hear arguments.

Canadian Supreme Court to hear high-profile patent dispute

Canada03-11-2014Legal developments

Canada’s highest court is set to hear a hotly anticipated dispute pitting generic company Apotex against drug companies Sanofi and Bristol-Myers Squibb (BMS).

Showing 761 to 770 of 919 results